Document is current
Any future updates will be listed below
-
Authors
Kuang, Chaoyuan https://orcid.org/0000-0002-8984-3906
Park, Yongseok
Augustin, Ryan C.
Lin, Yan
Hartman, Douglas J.
Seigh, Lindsey
Pai, Reetesh K.
Sun, Weijing
Bahary, Nathan
Ohr, James
Rhee, John C.
Marks, Stanley M.
Beasley, H. Scott
Shuai, Yongli
Herman, James G.
Zarour, Hassane M.
Chu, Edward
Lee, James J.
Krishnamurthy, Anuradha
-
Funding
Funding for this research was provided by:
National Cancer Institute (T32 CA193205)
Merck
- License Information
-
More Information
Article History
Received: 5 October 2021
Accepted: 28 December 2021
First Online: 6 January 2022
Declarations
:
: This study protocol was approved by the University of Pittsburgh Institutional Review Board. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
: All patients signed informed consent. Copies of informed consent are available upon request.
: WS is the principal investigator of an investigator-initiated trial using pembrolizumab. NB serves on advisory boards for AstraZeneca, Bristol Meyer Squibb, Exelixis, and ThermoFisher. The remaining authors declare no potential conflicts of interest.
